A Study of Tocilizumab in Patients With Rheumatoid Arthritis

Completed

Conditions studied: Rheumatoid Arthritis

In brief

This is an open-label, uncontrolled, observational study in patients with rheumatoid arthritis (RA) who are receiving tocilizumab concomitantly with methotrexate as part of their standard of care.

Key facts

Study ID

NCT01187563

Run by

Regeneron Pharmaceuticals

People needed

16

Starts

2010-08-01

Expected to finish

2010-12-01

Last updated by the study team

2011-10-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years of age
• Moderately to severely active rheumatoid arthritis
• Inadequate response to previous treatment with an anti-TNF agent
• Receiving methotrexate for at least 12 wks before study

You may not qualify if…

• Previous treatment with tocilizumab
• Previous treatment with other IL-6 receptor inhibitors
• Treatment with corticosteroids (oral prednisone >10 mg/day or equivalent) within 4 wks
• Conditions noted in the tocilizumab prescribing information

Where it is running

• Study site — Worcester, Massachusetts, United States
• Study site — Duncansville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.